Imunon (IMNN) Q3 2026 Earnings Call Transcript

Imunon (IMNN) reported Q3 2026 progress, highlighting Phase III IMNN-001 study for ovarian cancer. The company saw strong enrollment, independent validation, and a partnership with the National Cancer Institute. IMNN-001 aims to address a disease with low survival rates and limited treatment advances. The company expects 50% enrollment by Q1 2028 and completion by Q1 2029, with interim analysis in Q1 2030.

Original reporting
Published Nov 12, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Imunon (IMNN) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$IMNNBullishMed
01

Why it matters

The disclosed trial progress and partnership are first‑time material facts that could move the stock, while the asset sale adds cash but may reduce future pipeline breadth.

02

Market read

First‑time trial and partnership updates provide fresh catalyst for IMNN, with potential upside for investors.

03

What to watch

Potential regulatory hurdles for the CRADA and the timeline to market for IMNN-001.

Relevance 8/10Novelty 8/10Timing: immediate post‑call

Background

Imunon (IMNN) provided an earnings‑call style update covering its lead oncology candidate, a new research collaboration, and a divestiture.

Company-level read

Ticker impact

$IMNNBullishHigh confidence
Context

The transcript reveals progress on the Phase III OVATION-3 trial, a new CRADA with the National Cancer Institute, and the sale of ThermoDox rights, all first‑time disclosures.

Expected impact

likely upward pressure as investors price in continued trial momentum and additional capital from the ThermoDox sale

Evidence & confidence

Clinical data updates and a strategic partnership are material catalysts for a biotech; the cash infusion from the asset sale reduces burn.

Market effects

Strengthens the oncology biotech sector by showing viable IL‑12 platform progress.

May boost US biotech sentiment, limited impact elsewhere.

Limited to investors tracking oncology trial pipelines.

Counterpoint

Trial enrollment could slow, and the asset sale may signal focus shift away from ThermoDox.

Key entities

  • Imunon

    Biotech developing IMNN-001 for ovarian cancer.

  • National Cancer Institute

    Partner in a CRADA to evaluate IMNN-001 across additional indications.

  • VoxelDox Therapeutics

    Buyer of Imunon's ThermoDox rights.

Related articles

$IMNNLow

Imunon 3Q 2026: EPS ($0.64) — 10-Q Summary

Imunon (IMNN) reported a wider net loss of $3.81M in Q3 2026, though diluted EPS improved to ($0.64) from ($1.16) YoY. Operating expenses decreased 1%, with R&D costs down 6%. The OVATION 3 trial enrollment exceeded expectations, and the company advanced its NCI collaboration and MRD study. Imunon discontinued PLACCINE and IMNN-101 development in Q1 2026.

$IMNNMed

Imunon Reports Q3 2026 Net Loss of $3.8 Million and Advances IMNN-001

Imunon reported a Q3 2026 net loss of $3.8M, or $0.64 per share, compared to $3.4M, or $1.16 per share, a year earlier. Operating expenses were $3.4M. The company updated its Phase 3 ovarian cancer study and other programs, with enrollment expected to complete by Q1 2029. Imunon also transferred ThermoDox rights to VoxelDox, contingent on funding.

$IMNNHighAI 8/10

IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update

Imunon, Inc. (IMNN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IMUNON Reports Third Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollm

$IMNNHighAI 8/10

IMUNON presents translational data from ovarian cancer trial

IMUNON Inc. (IMNN) presented data from its Phase 2 OVATION 2 study of IMNN-001 in advanced ovarian cancer, showing improved survival and immune response. The trial compared IMNN-001 with chemotherapy against chemotherapy alone. The company is now conducting a Phase 3 trial, OVATION 3, to confirm these results. IMNN-001 is a DNA-based immunotherapy targeting IL-12 delivery to tumor tissue.

$IMNNMed

In an ovarian cancer trial, median survival was 14.7 months longer with added treatment

IMUNON, Inc. (Nasdaq: IMNN) announced new data from its Phase 2 OVATION 2 study, showing that IMNN-001 increased anti-tumoral T-cell activity in ovarian cancer patients. The treatment improved median overall survival by 14.7 months compared to standard care. The findings support the ongoing Phase 3 OVATION 3 trial. The data was presented at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting.

$IMNNMedAI 8/10

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Imunon (IMNN) held its Q2 2026 earnings call. Management reported Phase 2 OVATION II median overall survival of 45.1 months vs 30.4 months, and PARP maintenance survival of 65.6 vs 41.4 months. Q2 R&D was $1.5M, G&A $1.3M, net loss $2.8M. Cash was $6.9M after a $10M financing.